Genomic Large Rearrangement Screening of BRCA1 and BRCA2 Genes in High-Risk Turkish Breast/Ovarian Cancer Patients by Using Multiplex Ligation-Dependent Probe Amplification Assay

REFERENCES

• Bellosillo B, Tusquets I. Pitfalls and caveats in BRCA sequencing. Ultrastruct Pathol 2006;30:229–235.
   Web of Science ®Google Scholar
• Armour JA, Barton DE, Cockburn DJ, Taylor GR. The detection of large deletions or duplications in genomic DNA. Hum Mutat 2002;20(5):325–337.
   PubMed Web of Science ®Google Scholar
• Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250(4988):1684–1689.
   PubMed Web of Science ®Google Scholar
• Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyenk K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Develee P, Cornelisse CJ, Menko FH, Dalyp A, Ormiston W, Mcmanu R, Pye C, Lewis CM, Cannonalbright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265(5181):2088–2090.
   PubMed Web of Science ®Google Scholar
• Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 1997;57(5):828–831.
   PubMed Web of Science ®Google Scholar
• Vasickova P, Machackova E, Lukesova M, Damborsky J, Horky O, Pavlu H, Kuklova J, Kosinova V, Navratilova M, Foretova L. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet 2007;8:32.
   PubMedGoogle Scholar
• Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M, Zikan M, Pohlreich P. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Breast Cancer Res Treat 2010 Feb 5. [Epub ahead of print]. Doi:10.1007/s10549-010-0745-y.
   PubMed Web of Science ®Google Scholar
• Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJ, Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17(3):341–345.
   PubMed Web of Science ®Google Scholar
• Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D’Andrea E. Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 2003;12(9):1055–1061.
   PubMed Web of Science ®Google Scholar
• Moisan AM, Fortin J, Dumont M, Samson C, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Provencher L, Voyer P, Goldgar D, Bridge P, Simard J. No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genet Test 2006;10(2):104–115.
   PubMedGoogle Scholar
• Lahti-Domenici J, Rapakko K, Pääkkönen K, Allinen M, Nevanlinna H, Kujala M, Huusko P, Winqvist R. Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. Cancer Genet Cytogenet 2001;129(2):120–123.
   PubMed Web of Science ®Google Scholar
• Pylkäs K, Erkko H, Nikkilä J, Sólyom S, Winqvist R. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 2008;8: 146.
   Google Scholar
• The BRCA1 Exon 13 Duplication Screening Group. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 2000;67(1): 207–212.
   PubMed Web of Science ®Google Scholar
• Weischer M, Bojesen SE, Ellervik C, Tybjærg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008;26(4):542–548.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:215.
   Web of Science ®Google Scholar
• Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17(8): 857–872.
   PubMed Web of Science ®Google Scholar
• Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 2008;68(17):7006–7014.
   PubMed Web of Science ®Google Scholar
• Agata S, Dalla Palma M, Callegaro M, Scaini MC, Menin C, Ghiotto C, Nicoletto O, Zavagno G, Chieco-Bianchi L, D’Andrea E, Montagna M. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet 2005;42(10), e64.
   PubMed Web of Science ®Google Scholar
• Lim YK, Lau PT, Ali AB, Lee SC, Wong JE, Putti TC, Sng JH. Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. Clin Genet 2007;71(4):331–342.
   PubMed Web of Science ®Google Scholar
• Armaou S, Konstantopoulou I, Anagnostopoulos T, Razis E, Boukovinas I, Xenidis N, Fountzilas G, Yannoukakos D. Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. Eur J Cancer 2007;43(2):443–453.
   PubMed Web of Science ®Google Scholar
• Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska M, Palomba G, Pisano M, Casula M, Palmieri G, Borg A, Limon J. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep 2008;19(1):263–368.
   PubMed Web of Science ®Google Scholar
• Balci A, Huusko P, Pääkkönen K, Launonen V, Uner A, Ekmekçi A, Winqvist R. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer. Eur J Cancer. 1999;35(5):707–710.
   PubMed Web of Science ®Google Scholar
• Ozdag H, Tez M, Sayek I, Müslümanoglu M, Tarcan O, Içli F, Oztürk M, Ozçelik T. Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur J Cancer 2000;36(16): 2076–2082.
   PubMed Web of Science ®Google Scholar
• Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000;83(6):737–742.
   PubMed Web of Science ®Google Scholar
• Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat 2002;20(1):28–34.
   PubMed Web of Science ®Google Scholar
• Manguoglu AE, Lüleci G, Ozçelik T, Colak T, Schayek H, Akaydin M, Friedman E. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003;21(4):444–445.
   PubMedGoogle Scholar
• Güran S, Ozet A, Dede M, Gille JJ, Yenen MC. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis. Cancer Genet Cytogenet 2005;160(2): 164–168.
   PubMed Web of Science ®Google Scholar
• Egeli U, Cecener G, Tunca B, Tasdelen I. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Invest 2006;24(5):484–491.
   PubMed Web of Science ®Google Scholar
• CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74(6):1175–1182.
   PubMed Web of Science ®Google Scholar
• Fletcher O, Johnson N, Dos Santos Silva I, Kilpivaara O, Aittomäki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dörk T, Chekmariova EV, Sokolenko AP, Imyanitov EN, Hamann U, Rashid MU, Brauch H, Justenhoven C, Ashworth A, Peto J. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 2009;18(1):230–234.
   PubMed Web of Science ®Google Scholar
• Thirthagiri E, Cheong LS, Yip CH, Teo SH. CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia. Fam Cancer 2009;8(4), 355–358.
   PubMed Web of Science ®Google Scholar